ID: ALA200256

Max Phase: Preclinical

Molecular Formula: C23H16N4O4

Molecular Weight: 412.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1[nH]c(-c2ccc3c(n2)C(=O)C(=N)C=C3O)c2nc3ccccc3c-2c1C

Standard InChI:  InChI=1S/C23H16N4O4/c1-10-17-11-5-3-4-6-14(11)25-21(17)20(27-18(10)23(30)31-2)15-8-7-12-16(28)9-13(24)22(29)19(12)26-15/h3-9,24,27-28H,1-2H3

Standard InChI Key:  XRCXVGNLBLGWBQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 412.41

Molecular Weight (Monoisotopic): 412.1172

AlogP: 3.94

#Rotatable Bonds: 2

Polar Surface Area: 129.02

Molecular Species: ACID

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.64

CX Basic pKa: 3.13

CX LogP: 3.64

CX LogD: 1.79

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.43

Np Likeness Score: 0.01

References

1. Hassani M, Cai W, Holley DC, Lineswala JP, Maharjan BR, Ebrahimian GR, Seradj H, Stocksdale MG, Mohammadi F, Marvin CC, Gerdes JM, Beall HD, Behforouz M..  (2005)  Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.,  48  (24): [PMID:16302813] [10.1021/jm050758z]

2. Hassani M, Cai W, Koelsch KH, Holley DC, Rose AS, Olang F, Lineswala JP, Holloway WG, Gerdes JM, Behforouz M, Beall HD..  (2008)  Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.,  51  (11): [PMID:18457384] [10.1021/jm701066a]

Source

Source(1):

• Scientific Literature